CMPS COMPASS Pathways
- 8.120
- +0.260+3.31%
- 8.250
- +0.130+1.60%
COMPASS Pathways News
COMPASS Pathways Plc (NASDAQ:CMPS) Q1 2024 Earnings Call Transcript
HC Wainwright & Co. : The Compass Pathways (CMPS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $120.00.
HC Wainwright & Co. : The Compass Pathways (CMPS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $120.00.
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Compass Pathways with a Buy and maintains $120 price target.
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1357.99% HC Wainwright & Co. → $120 Reiterates Buy → Buy 04/30/2024 — Cantor Fitzgerald Reiter
Earnings Call Summary | COMPASS Pathways(CMPS.US) Q1 2024 Earnings Conference
The following is a summary of the COMPASS Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript:Financial Performance:COMPASS Pathways had a net cash usage in operations of $20.8 million in Q1 2024 and
COMPASS Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript
Buy Rating Affirmed for COMPASS Pathways Amid Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Rapid Micro Biosystems (RPID), COMPASS Pathways (CMPS) and Harrow Health (HROW)
COMPASS Pathways (CMPS) Receives a Buy From Oppenheimer
Pot Company Gets License To Open Psilocybin Service Center, The Sacred Mushroom, In Oregon
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate a Psilocybin Service Center.Oregon is the only state in
COMPASS Pathways' COMP360 Shows Promise in Mental Health: A Buy Rating Amid Positive Trial Outcomes and Strategic R&D Leadership
Compass Pathways Plc (CMPS) Q1 2024 Earnings Call Transcript
Compass Pathways Reports Q1 Cash And Cash Equivalents Of $262.9M
Second quarter 2024 net cash used in operating activities is expected to be in the range of $32 million to $38 million.The full-year 2024 net cash used in operating activities is expected to be in the
Compass Pathways Q1 2024 GAAP EPS $(0.55) Misses $(0.48) Estimate
Compass Pathways Q1 2024 GAAP EPS $(0.55) Misses $(0.48) Estimate
COMPASS Pathways | 10-Q: Quarterly report
Press Release: Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights
Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights -- COMP360 phase 3 pivotal program in treatment-resistant depression (TRD) on track for top-line COMP0
Compass Pathways 1Q Loss $35.2M >CMPS
Compass Pathways 1Q Loss $35.2M >CMPS
Compass Pathways 1Q Loss/Shr 55c >CMPS
Compass Pathways 1Q Loss/Shr 55c >CMPS
Compass Pathways Announced Topline Results From An Open-label Phase 2 Study Of COMP360 Psilocybin Treatment For Post-Traumatic Stress Disorder, The Study Met Its Primary Safety Endpoint And Available Secondary Efficacy Endpoints
Study met primary safety endpoint; administration was well tolerated, with no serious adverse events observedEarly and clinically meaningful improvement from baseline in mean CAPS-5 total score (29.5
"FDA Expert Committee Will Review MDMA-Assisted Therapy For PTSD Next Month" - Marijuana Moment
The Food and Drug Administration (FDA) is taking the next step in its historic review of MDMA-assisted therapy for the treatment of post-traumatic stress disorder (PTSD), scheduling a meeting next mon
Analysis
Price Target
No Data
